General description


    Combivir is indicated for treatment of HIV infection.

    Recommended dosage for adults and adolescents at least 12 years of age is one tablet (150 mg lamivudine, 300 mg zidovudine) twice daily. Patients requiring reduced dosage should not receive Combivir.

    Combivir is a fixed-dosage drug, and as such, those patients who require reduced dosage for treatment should not receive Combivir. This includes patients with low body weight (less than 50 kg or 110 lbs) as well as patients with renal and liver dysfunction Patients should be informed that Combivir is not a cure for HIV- transmission is still possible during treatment, as is the progression of HIV disease itself. Combination treatment with ganciclovir, interpheron-alpha,bone marrow suppressives, and cytotoxic agents can increase change of hemotoxicity of Combivir.

    Combivir is contraindicated for any patients with known allergies to any components of the drug. Patients with low body weight and severe liver and kidney dysfunction should not reveive Combivir. Warnings for other drugs should also be consulted before beginning any combination treatment program. Patients with bone marrow compromise have higher rates of anemia and neutropenia, so caution should be exercised.

Potential Adverse Effects
    The most common effects are headache, anesthenia, malaise, nausea, diarrhea, nasal signs and symptoms, and cough. Lactic acidosis, pancreatitis, vasculitis, and sensitization reactions are all severe effects that have been reported, however. Adverse reactions tend to worsen as HIV disease progresses, so patients should be monitored.